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Introduction
Worldwide, breast cancer is the most common cancer 
found among women and the leading cause of deaths. 
According to the American Cancer Society, approximately 
232,340 new of invasive cases and 39,620 deaths are 
expected to occur among US women in 2013. One in 8 
women in the United States will develop breast cancer in 
her lifetime. The rate of incidence rates increased slightly 
among African American women; decreased among 
Hispanic women; and remained stable among whites, 
Asian Americans/Pacific Islanders, and American Indians/
Alaska natives from 2006 to 2010 (Althuis et al., 2005). 
Global differences in incidence rates and fluctuations in 
rates within a country are both affected by changes in 
risk factor for prevalence and secular trends in diagnosis 
(DeSantis et al., 2014).
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Abstract
 Background: Worldwide, breast cancer is the most common cancer diagnosed among women and a leading 
cause of cancer deaths. The age of onset in Iran has become reduced by a decade for unknown reasons. Herceptin, 
a humanized monoclonal antibody, is a target therapy for breast cancer cells with over expression of HER2-
neu receptors, but it is an expensive drug with only 20% beneficial rate of survival. This study introduces a 
novel approach to enhance the efficacy of this drug through immunoconjugation of the antibody to botulinum 
toxin. Decreasing the cost and adverse effects of the antibody were secondary goals of this study. Materials and 
Methods: Botulinum toxin was conjugated with Herceptin using heterobifunctional cross linkers, succinimidyl 
acetylthiopropionate (SATP) and sulfo-succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC) 
according to the supplier’s guidelines and tested on two breast cancer cell lines: SK-BR-3 and BT-474. Toxin 
and Herceptin were also used separately as controls. The cytotoxicity assay was also performed using the new 
bioconjugate on cultured cells with Alamar blue and a fluorescence plate reader. Results: Herceptin-Toxin 
bioconjugation significantly improved Herceptin efficacy on both breast cancer cell lines when compared to 
the control group. Conclusions: Toxin-Herceptin bioconjugation can be a potential candidate with increased 
efficiency for treating breast cancer patients with over expression of the HER2 receptor. 
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The peak incidence of breast cancer in Iran is between 
the ages 40-50, which is a decade younger than that of the 
western countries (Hosseini et al., 2013). In Iran, it ranks 
first among cancers diagnosed in women and the fifth most 
common cause of death (Taghavi et al., 2012). Although 
the exact cause is not known, genetic and environmental 
factors seem to play roles. 
The human epidermal growth factor receptor-2 gene 
C-Erb2/neu (also known as HER2/neu) encodes 1255 
amino acids to a membrane glycoprotein receptor of 185KD 
from the tyrosine kinase family (Kaufmann et al., 2011). 
HER2 receptor regulate cell growth and differentiation 
through specific signal transduction pathways. HER2 gene 
amplification on chromosome 17 accounts for about 25% 
of over expressions leading to tumor growth, lengthening 
the S phase in cell cycle, aneuploidy and down-regulation 
of estrogen and progesterone receptors (d’Agnano et al., 
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1996; Alshenawy, 2012).
Herceptin (Trastuzumab) is a humanized monoclonal 
IgG1 kappa antibody that selectively binds with high 
affinity to the extracellular domain of HER2 receptors 
with high affinity (Beuzeboc et al., 1999). Trastuzumab 
induces down modulation of HER2 receptor and, as a 
result, inhibits critical signalling pathways (i.e. ras-Raf-
MAPK and PI3K/Akt) and blocks cell cycle progression 
by inducing the formation of p27/Cdk2 complexes. 
Trastuzumab also inhibits HER2 cleavage, preceding 
antibody-induced receptor down modulation that in 
turn contribute to its antitumor activity in some tumor 
cells. Moreover, trastuzumab have shown to inhibits 
angiogenesis and induces antibody-dependent cellular 
cytotoxicity (Albanell et al., 2003).Immunotheraputic 
administration of Herceptin is a promising new approach 
in breast cancer treatment, complementing surgery, and 
other therapy such as chemotherapy, radiation and anti-
hormonal therapy (Untch et al., 2003). Inspite of these 
advances Herceptin is an expensive intervention with side 
effects such as: cardiovascular adverse events (Tsai et al., 
2014) leukopenia, hypotension, dyspnea, anemia, fatigue, 
headache, fever, diarrhea (Dang et al., 2010), and skin rash 
(Adachi et al., 2011). Nevertheless its activity is largely 
restricted to treatment and management of breast cancers 
cases with the highest level of HER2 gene amplification 
(Albanell et al., 2003).
Botulinum toxin is a neurotoxin produced by the 
bacterium Clostridium Botulinum (Yoneyama et al., 
2008). To date eight serotypes of this toxin (A through 
H) have been identified. The toxin endocytosed after 
binding to neurons and inhibits acetylcholine release 
via the photolytic activity of its catalytic domain (Ray, 
1993). Some medical applications of Botulinum Toxin 
include treating children with cerebral palsy (Nezu and 
Iwasaki, 2013), overactive bladder(Ravindra et al., 2013), 
excessive sweating (Naumann et al., 2002), chronic 
migraine prevention of salivary stagnation after surgery of 
oral cavity cancer (Corradino et al., 2012) and controlling 
pain after mastectomy (Layeeque et al., 2004). Botulinum 
Toxin is also shown to induce apoptosis in T47D breast 
cancer cell line through caspase-3 and -7 pathways 
(Bandala et al., 2013).
In this study we conjugated Herceptin to Botulinum 
to enhance its efficiency and possibly reducing the 
therapeutic dose of the drug.
Materials and Methods
Herceptin preparation and activation:
100 mg Herceptin was dissolved in deionized water 
and transferred to a dialysis bag containing 50 mM 
phosphate buffer (pH: 7.5), contains 1 mM EDTA, and 
kept for 12 hours at 4˚C to remove small molecules from 
Herceptin. 300µl Herceptin (5mg/ml) was mixed with 
20µl SATP (N-succinimidyl-S-acetylthiopropionate) 
solution and incubated for 60 minutes at room temperature 
and passed through superdex G-10 chromatography 
column to remove excess SAPT from antibody solution. 
50 µl Hydroxyl amine solution was also added to 500 
µl Herceptin-SATP to protect the –SH groups. After 2 
hours of incubation the solution was dialyzed in 50 mM 
phosphate buffer (pH: 7.5), contains 1 mM EDTA, for 
12 hours at 4˚C.
Botulinum Toxin preparation and activation:
250 µl toxin aqueous solution (1mg/ml) was dialyzed 
in 0.1 mM phosphate buffer (pH: 7.5), contains 1 mM 
EDTA, for 12 hours at 4˚C and ultra-centrifuged at 4˚C 
to remove the accompanying materials.
Immunotoxin preparation:
150µL concentrated Botulinum Toxin was added to 
the same volume of Herceptin-SATP (molar ratio1:1) in a 
microtube and the mixture was wrapped in aluminum foil 
and kept for 18 hours at room temperature (Li et al., 2008).
High-Performance Liquid Chromatography (HPLC) 
Testing:
Diol-200-8.0X500-DL20S05-5008WT column was 
used to confirm the bioconjugation reaction by HPLC 
analysis. For column preparation, 0.1 M phosphate buffer 
including 0.15 NaCl was flown through the column at 
least for 1 hour. Then 10 µl of each samples was run for 
50 minutes, and sample concentration was calculated by 
OD measurement at 280nm.
Cell culture
Two breast cancer cell lines; SK-BR-3 and BT-
474; were purchased from Pasteur Institute of Iran and 
cultured at standard conditions at 37˚C, 95% humidity 
and 5%. The culture medium was replaced at 48 and 72 
hour intervals, to feed the cell lines and maintain the cell 
growth. Each cultured cell line was divided into four 
groups, based on the following treatments: Group 1: 
Cells + medium + Botulinum toxin (20 µg/ml); Group 2: 
Cells + medium + Herceptin (20 µg/ml); Group 3: Cells 
+ medium + Botulinum-Herceptin(20 µg/ml); Group 4: 
Cells + medium
Alamar blue (25µl) was added to the wells after 5 
days and the fluorescence intensity was measured using 
a fluorescence reader at wavelengths 530nm (excitation) 
and 605nm (emission) to monitor the cell viability.
Results 
HPLC procedures: The HPLC analysis of the 
bioconjugate preperation was performed according 
to the figure legends to find out various HPLC peaks 
for Trastuzumab, the toxin and the bioconjugate 
(immunotoxin) to ensure proper conjugation of two 
components (antibody and toxin).
As it is shown in figure 1, the second peak (Retention 
Time=28.542min) corresponds to the toxin. Peak 
1 represents oligomeric form of the toxin, peak 2 
corresponds to the monomeric form of the toxin, Peaks 
3 and 4 correspond to the small molecules in the toxin 
buffer matrix.
Figure 2 shows the chromatogram of Herceptin, in 
which only one peak can be seen to respect the antibody 
monomer without any other contaminations or component.
Figure 3 shows the HPLC Analysis of the conjugation 
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reaction mixture. Chromatographic conditions were the 
same as figure 1. The first and second peaks correspond 
to the bioconjugat molecules at two different molecular 
ratio. The conjugation precedures combine 1-3 molecules 
of toxin per antibody molecules. The two peaks here, 
coresponds to 1-3 bioconjugate molecules based on the 
molecular ratio of both molecules, and the 3rd and 4th 
peaks corespond to non-conjugated biomolecules.
Cell culture results: 
We observed a substantial reduction in the number 
of cells (94.96% and 95.8% in BT-474 and SK-BR-3 
respectively) in both cell lines when treated with the 
bioconjugate when compared to the untreated control. 
Herceptin alone showed higher efficacy on BT-474 
cell line (figure 4) compared to a condition where the 
antibody tested on SK-BR-3 cells (figure 5). Decrease in 
cell viability was also more dramatic when BT-474 cells 
treated with the bioconjugate. 
Discussion
 Resistance to Herceptin therapy has been documented 
in majority of patients with HER2 over expression (Ahmad 
et al., 2014). Only 20% of patients with amplified HER2/
neu response to Herceptin. Moreover; A cardio toxicity 
profile has been described in more than 10 percent of the 
patients who used Herceptin, thus its dosage needs to be 
carefully adjusted and tailored to each patient, especially 
in elderly patients with cardiovascular problems (Sparano, 
2001). 
 The new bioconjugate (immunotoxin) showed 
significant reduction in the viability of BT-474 and SK-
BR-3 cell lines compared to both Herceptin and botulinum 
toxin individually. This result indicates significant 
synergistic reduction effect of bioconjugated drug on 
cancer cells viability 94.96% and 95.8% in BT-474 and 
SK-BR-3 respectively.
 The efficacy of conventional cytotoxic medications 
is directly related to the ratio of dividing tumor cells 
to healthy cells, as they are distributed to all tissues 
through blood due to their low molecular weight and 
Figure 1. Chromatogram of the Toxin; Peak 1: 
Oligomeric Protein; peak 2: Monomeric Protein; Peak 
3&4: Small Molecules. Column: YMC-Pack Diol-200-
8.0X500-DL20S05-5008WT, Mobile phase: 0.1M Phosphate 
buffered saline (PBS) with 0.15M NaCl. Injection volume: 10µl. 
Runtime: 50 minutes. Detector: Ultraviolet Wavelength: 280nm. 
Flow rate: 0.5 ml/min
Figure 2. HPLC chromatograph of Herceptin: the peak 
Corresponds to Purified Herceptin (Retention Time: 
28.608min). All the Chromatographic Conditions were the 
Same as Figure 1
Figure 3. HPLC chromatograph of the Bioconjugate; 
Peaks 1&2: Toxin-antibody Bioconjugate; Peaks 3&4: 
Small Bounded Co-molecules
Figure 4. Fluorescence Intensity (average +/- standard 
deviation) of BT-474 Cell Line in Different Groups 
shows Significant Reduction (94.96%) in Cell Viability 
in the Bioconjugate Group (P<0.001)
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Figure 5. Fluorescence Intensity (Average +/-Standard 
deviation) of SK-BR-3 Cell Line in Different Groups 
Shows Significant Reduction (95.8%) Cell Viability in 
the Bioconjugate Group (P < 0.001)
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lack of specificity. This will in turn lead to adverse side 
effects and resistance. In the last decade recombinant 
biopharmaceuticals have contributed in many novel 
therapeutics with higher specificity which renders 
them more effective and more tolerable (Olver, 2008). 
Researchers attach cytotoxins to macromolecules (e.g. 
antibodies, serum proteins, lectins, peptides, growth 
factors and synthetic polymers) to enhance their efficacy 
and reduce the unwanted effects. Antibodies play an 
important role in cancer therapies, their activity however, 
is short lived (Meyer et al., 2014).
 Immunotoxin consist of a toxin attached to an antibody 
or a growth factor with a specific target to enter the 
cytoplasm and to mediate their effects on the normal cells 
(Avila et al., 2007; Singh et al., 2007). The bioconjugate 
improves the therapeutic profile of the antibody by 
increasing its tissue distribution, reducing its side effect 
on the healthy cells and increasing the half-life of the 
medication. In vivo experiments and clinical trials have 
established the effectiveness of new bioconjugates (Dao 
et al., 2012). 
 The first effective immunotoxins were plant derived 
toxins like ricin that could inhibit protein synthesis 
via inhibiting ribosomal RNA (Chan et al., 2004) and 
vascular injuries associated with this drug ameliorated 
by genetic modifications of Ricin A chain (Mohanraj and 
Ramakrishnan, 1995). Other herbal cytotoxins include: 
Saporin, Gelonin and Poke weed. Immunotoxins can 
inhibit cell growth through inhibiting protein synthesis 
and inducing apoptosis. (Houchins, 2000) Anti-c-Met/
PE38KDEL for instance, targets stomach cells in this 
manner (Wei et al., 2011).
 Breast cancer is the most prevalent cancer among 
women worldwide and the most frequent malignancy 
among Iranian women over the past few decades 
(Afsharfard et al., 2013), with an increasing trend. 
Herceptin (Trastuzumab) is a monoclonal antibody 
against the extracellular domain of HER2 with humanized 
complementary-determining regions (CDRs) of 
monoclonal antibody 4D5 (Albanell and Baselga, 1999). 
Herceptin therapy adjuvant to chemotherapy has shown 
to increase therapeutic response and survival in HER2/
neu positive patients (Perez, 2001)
 Barok et al investigated the effect of a new conjugate 
trastuzumab-DM1 on four gastric cancer cell lines (N-87, 
OE-19, SNU-216 and MKN-7). N-87 and OE-19 showed 
greater sensitivity compared to Herceptin alone. MKN-7 
showed moderate response while a limited efficacy was 
observed in SNU-216. The study was performed in in-vitro 
setting where its analysis supported our data (Barok et al., 
2011). 
 Lattová et al used Herceptin in combination with 
Lipoplex mixed with plasmid DNA against Herceptin 
resistant cell lines and showed a positive response when 
measured by trypan blue after 72 hours (Lattova et al., 
2010). In this study we used Alamar blue which is more 
sensitive than trypan blue.
 Similar in-vitro and in-vivo experiments have 
confirmed the efficacy of immunotoxins in treatment of 
different types of malignancies. Moreover we can isolate 
the light chain of the toxin responsible for its protease 
activity and utilize the Herceptin to function as the toxin 
heavy chain for cell targeting and endocytosis.
 Finally, this study demonstrated an increase in the 
efficacy of Herceptin when bound to Botulinum toxin. 
This could in turn lead to a lower dose of administration 
and therefore lower rates of adverse side effects.
 For further study, in animal model, the L-Chain of the 
Botulinum Toxin needs to be separated from cell-bind 
domain and conjugated into antibody in order to prevent 
destructive effect on normal cells. 
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